Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marchesoni

Showing results (431-440 of 521) with videos related to

Pageof 53
Sort By:
Rheumatology (Oxford, England)|March 13, 2010
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year studyAntonio Spadaro, Leonardo Punzi, Antonio Marchesoni, et al.
Psychiatry Research|August 30, 2023
Use and misuse of the emergency room by patients with eating disorders in a matched-cohort analysis: What can we learn from it?Giovanni Castellini, Emanuele Cassioli, Eleonora Rossi, et al.
Cancer Letters|March 6, 2003
A novel Q3034R BRCA2 germline mutation identified in a fallopian tube cancer patientFrancesco Baudi, Loredana De Paola, Barbara Quaresima, et al.
Rheumatology and Therapy|October 1, 2021
Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-AnalysisAlen Zabotti, Orazio De Lucia, Garifallia Sakellariou, et al.
Clinical and Experimental Rheumatology|February 16, 2019
Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEAFabiola Atzeni, Piercarlo Sarzi-Puttini, Marco Sebastiani, et al.
Clinical and Experimental Rheumatology|May 23, 2014
The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritisAntonio Spadaro, Ennio Lubrano, Antonio Marchesoni, et al.
Joint Bone Spine|February 27, 2025
Clinical and ultrasonographic predictors of disease activity after TNF-α inhibitor spacing in patients with psoriatic arthritisAntonio Marchesoni, Pierluigi Macchioni, Giovanni Ciancio, et al.
Trials|August 10, 2023
Organisational models supported by technology for the management of diabetic disease and its complications in a diabetic clinic setting: study protocol for a randomised controlled trial targeting type 2 diabetes individuals with non-ideal glycaemic values (Telemechron study)Alexia Giovanazzi, Lorenzo Gios, Marina Mastellaro, et al.
Clinical and Experimental Rheumatology|October 31, 2024
A new instrument for the screening of psoriatic arthritis among psoriatic patientsGabriele De Marco, Antonio Marchesoni, Maria Manara, et al.
Joint Bone Spine|September 13, 2017
Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugsFabiola Atzeni, Antonio Carletto, Rosario Foti, et al.
Pageof 53

Showing results (431-440 of 521) with videos related to

Sort By:
Pageof 53
Rheumatology (Oxford, England)|March 13, 2010
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year studyAntonio Spadaro, Leonardo Punzi, Antonio Marchesoni, et al.
Psychiatry Research|August 30, 2023
Use and misuse of the emergency room by patients with eating disorders in a matched-cohort analysis: What can we learn from it?Giovanni Castellini, Emanuele Cassioli, Eleonora Rossi, et al.
Cancer Letters|March 6, 2003
A novel Q3034R BRCA2 germline mutation identified in a fallopian tube cancer patientFrancesco Baudi, Loredana De Paola, Barbara Quaresima, et al.
Rheumatology and Therapy|October 1, 2021
Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-AnalysisAlen Zabotti, Orazio De Lucia, Garifallia Sakellariou, et al.
Clinical and Experimental Rheumatology|February 16, 2019
Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEAFabiola Atzeni, Piercarlo Sarzi-Puttini, Marco Sebastiani, et al.
Clinical and Experimental Rheumatology|May 23, 2014
The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritisAntonio Spadaro, Ennio Lubrano, Antonio Marchesoni, et al.
Joint Bone Spine|February 27, 2025
Clinical and ultrasonographic predictors of disease activity after TNF-α inhibitor spacing in patients with psoriatic arthritisAntonio Marchesoni, Pierluigi Macchioni, Giovanni Ciancio, et al.
Trials|August 10, 2023
Organisational models supported by technology for the management of diabetic disease and its complications in a diabetic clinic setting: study protocol for a randomised controlled trial targeting type 2 diabetes individuals with non-ideal glycaemic values (Telemechron study)Alexia Giovanazzi, Lorenzo Gios, Marina Mastellaro, et al.
Clinical and Experimental Rheumatology|October 31, 2024
A new instrument for the screening of psoriatic arthritis among psoriatic patientsGabriele De Marco, Antonio Marchesoni, Maria Manara, et al.
Joint Bone Spine|September 13, 2017
Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugsFabiola Atzeni, Antonio Carletto, Rosario Foti, et al.
Pageof 53